<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Alternative endocrine therapies for castration-resistant prostate cancer
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Alternative endocrine therapies for castration-resistant prostate cancer
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Alternative endocrine therapies for castration-resistant prostate cancer
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Nancy A Dawson, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            W Robert Lee, MD, MS, MEd
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jerome P Richie, MD, FACS
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Melinda Yushak, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 22, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Androgen deprivation therapy (ADT) is generally the initial treatment for males with advanced prostate cancer, in combination with chemotherapy or combined with a second-generation androgen-targeted therapy or both. Standard approaches to first-line ADT include orchiectomy, a gonadotropin-releasing hormone (GnRH) agonist, or a GnRH antagonist. (See
         <a class="medical medical_review" href="/z/d/html/6951.html" rel="external">
          "Initial systemic therapy for advanced, recurrent, and metastatic noncastrate (castration-sensitive) prostate cancer"
         </a>
         .)
        </p>
        <p>
         Despite initial response rates of 80 to 90 percent, nearly all males eventually develop castration-resistant disease, which is typically metastatic. Patients who develop progressive disease after their initial ADT are considered to have castration-resistant prostate cancer (CRPC), although their disease may respond to secondary endocrine therapies. In this setting, two agents,
         <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">
          abiraterone
         </a>
         (an inhibitor of androgen synthesis) and
         <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">
          enzalutamide
         </a>
         (a potent and selective inhibitor of the androgen receptor), have been shown to prolong overall survival and are the preferred systemic therapies when endocrine therapy is indicated  (
         <a class="graphic graphic_table graphicRef127197" href="/z/d/graphic/127197.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/16351.html" rel="external">
          "Castration-resistant prostate cancer: Treatments targeting the androgen pathway", section on 'Abiraterone'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16351.html" rel="external">
          "Castration-resistant prostate cancer: Treatments targeting the androgen pathway", section on 'Enzalutamide'
         </a>
         .)
        </p>
        <p>
         Several alternative endocrine approaches (other older antiandrogens, antiandrogen withdrawal,
         <a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">
          ketoconazole
         </a>
         , glucocorticoids,
         <a class="drug drug_general" data-topicid="9603" href="/z/d/drug information/9603.html" rel="external">
          megestrol acetate
         </a>
         , estrogens) appear to be less effective and have not been demonstrated to improve survival. However, these approaches may induce clinical responses or stable disease. These alternative endocrine therapies are often used sequentially and may be useful in postponing interventions such as chemotherapy, with its associated toxicity, or after chemotherapy when no other effective options are available.
        </p>
        <p>
         These alternative endocrine approaches are discussed in this topic.
        </p>
        <p>
         Overviews of the management of advanced castration-sensitive prostate cancer and CRPC are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/6941.html" rel="external">
          "Overview of systemic treatment for recurrent or metastatic castration-sensitive prostate cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/112896.html" rel="external">
          "Overview of the treatment of castration-resistant prostate cancer (CRPC)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          CONTINUATION OF ANDROGEN DEPRIVATION THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Androgen deprivation therapy (ADT) is generally continued in conjunction with secondary therapies after progression on the initial ADT regimen [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/112896.html" rel="external">
          "Overview of the treatment of castration-resistant prostate cancer (CRPC)", section on 'Continuation of androgen deprivation therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H442096111">
         <span class="h1">
          ANTIANDROGENS AND ANTIANDROGEN WITHDRAWAL
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antiandrogens are drugs that interfere with the androgen receptor (AR) signaling pathway. Antiandrogens may be used as the initial treatment in males with CRPC, or they may be used sequentially after newer agents that have been demonstrated to increase overall survival  (
         <a class="graphic graphic_table graphicRef127197" href="/z/d/graphic/127197.html" rel="external">
          table 1
         </a>
         ). Antiandrogens are also sometimes used as part of a combined androgen blockade for the initial treatment of males with advanced castration-sensitive prostate cancer. (See
         <a class="medical medical_review" href="/z/d/html/112896.html" rel="external">
          "Overview of the treatment of castration-resistant prostate cancer (CRPC)", section on 'Interference with androgenic stimulation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6951.html" rel="external">
          "Initial systemic therapy for advanced, recurrent, and metastatic noncastrate (castration-sensitive) prostate cancer", section on 'ADT plus first-generation antiandrogens'
         </a>
         .)
        </p>
        <p>
         For males with CRPC, antiandrogens are generally given in the context of continued gonadotropin-releasing hormone (GnRH) agonist therapy or in males who have undergone orchiectomy. All of the antiandrogens have side effects related to the deprivation of androgen effect. These include loss of libido, impotence, hot flashes, and breast tenderness and/or gynecomastia.
        </p>
        <p class="headingAnchor" id="H201366679">
         <span class="h2">
          Abiraterone and enzalutamide
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">
          Abiraterone
         </a>
         (which blocks the synthesis of androgens) and
         <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">
          enzalutamide
         </a>
         (which acts at multiple sites in the AR signaling pathway) generally are the initial choice for second-line endocrine therapy in males with CRPC after failure of initial androgen deprivation therapy as long as they have not already received these agents as part of initial therapy for castration-sensitive disease. (See
         <a class="medical medical_review" href="/z/d/html/16351.html" rel="external">
          "Castration-resistant prostate cancer: Treatments targeting the androgen pathway", section on 'Abiraterone'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16351.html" rel="external">
          "Castration-resistant prostate cancer: Treatments targeting the androgen pathway", section on 'Enzalutamide'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6941.html" rel="external">
          "Overview of systemic treatment for recurrent or metastatic castration-sensitive prostate cancer", section on 'Triplet therapy (preferred)'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6941.html" rel="external">
          "Overview of systemic treatment for recurrent or metastatic castration-sensitive prostate cancer", section on 'Patients with Metastatic Disease'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Older antiandrogens
         </span>
         <span class="headingEndMark">
          —
         </span>
         Older antiandrogens primarily act by blocking the binding of dihydrotestosterone to the androgen receptor.
         <a class="drug drug_general" data-topicid="8471" href="/z/d/drug information/8471.html" rel="external">
          Flutamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9154" href="/z/d/drug information/9154.html" rel="external">
          bicalutamide
         </a>
         , and
         <a class="drug drug_general" data-topicid="9701" href="/z/d/drug information/9701.html" rel="external">
          nilutamide
         </a>
         are older antiandrogens that are used less often given the availability and superior efficacy of
         <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">
          abiraterone
         </a>
         and
         <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">
          enzalutamide
         </a>
         [
         <a href="#rid2">
          2,3
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/112896.html" rel="external">
          "Overview of the treatment of castration-resistant prostate cancer (CRPC)", section on 'Interference with androgenic stimulation'
         </a>
         .)
        </p>
        <p>
         These agents are often rotated and used sequentially when progressive disease occurs, based on the assumption that specific antiandrogens interact differently with the androgen receptor. The potential utility of switching antiandrogens was illustrated by a retrospective series of 232 patients who progressed after initial treatment with combined androgen blockade [
         <a href="#rid4">
          4
         </a>
         ]. After observation for an antiandrogen response, patients were treated with an alternative nonsteroidal antiandrogen. Overall, a prostate-specific antigen (PSA) decrease ≥50 percent was observed in 36 percent of patients, and a PSA decrease &lt;50 percent was seen in another 25 percent. These results antedate the development of
         <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">
          enzalutamide
         </a>
         and
         <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">
          abiraterone
         </a>
         , and there are only very limited data on the efficacy of these agents after progression with one of these agents.
        </p>
        <p>
         In locations where
         <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">
          abiraterone
         </a>
         and
         <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">
          enzalutamide
         </a>
         are not available and where first-generation antiandrogens are still used,
         <a class="drug drug_general" data-topicid="9154" href="/z/d/drug information/9154.html" rel="external">
          bicalutamide
         </a>
         is the preferred agent, based on a better toxicity profile and more efficacy in the large randomized trials that established its role in males with CRPC. Other antiandrogens may be used in sequential fashion after bicalutamide.
         <a class="drug drug_general" data-topicid="9701" href="/z/d/drug information/9701.html" rel="external">
          Nilutamide
         </a>
         is often the second antiandrogen used, although it can cause problems with light-dark adaptation, and there is a risk of pulmonary toxicity.
         <a class="drug drug_general" data-topicid="8471" href="/z/d/drug information/8471.html" rel="external">
          Flutamide
         </a>
         is seldom used because it has been associated with significant hepatic toxicity and deaths from liver failure.
        </p>
        <p class="headingAnchor" id="H5705197">
         <span class="h3">
          Bicalutamide
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9154" href="/z/d/drug information/9154.html" rel="external">
          Bicalutamide
         </a>
         is the preferred antiandrogen based on its activity and favorable toxicity profile. It may be used immediately in males with CRPC after initial GnRH agonist therapy or orchiectomy, or it may have utility after newer agents  (
         <a class="graphic graphic_table graphicRef127197" href="/z/d/graphic/127197.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9154" href="/z/d/drug information/9154.html" rel="external">
          Bicalutamide
         </a>
         (50 mg/day) has a half-life of approximately five to six days and is administered orally once a day in conjunction with a GnRH agonist. In addition to the side effects due to androgen deprivation, less common side effects include transient liver function abnormalities in less than 5 percent of patients and diarrhea in 10 percent.
        </p>
        <p>
         Although there is a biologic rationale for using higher doses of
         <a class="drug drug_general" data-topicid="9154" href="/z/d/drug information/9154.html" rel="external">
          bicalutamide
         </a>
         , results from clinical studies do not suggest that high-dose bicalutamide is more effective than standard-dose bicalutamide. In one study of 51 males receiving bicalutamide at a dose of 200 mg/day, PSA declines of 50 percent or greater were documented in 12 (24 percent) [
         <a href="#rid5">
          5
         </a>
         ]. Similar results were noted in two other series using a dose of 150 mg/day [
         <a href="#rid6">
          6,7
         </a>
         ].
        </p>
        <p>
         Although
         <a class="drug drug_general" data-topicid="9154" href="/z/d/drug information/9154.html" rel="external">
          bicalutamide
         </a>
         has clinical activity and is useful in appropriate clinical settings, it is significantly less active than newer antiandrogens, such as
         <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">
          enzalutamide
         </a>
         . In two randomized clinical trials in chemotherapy-naïve CRPC, enzalutamide significantly prolonged progression-free survival compared with bicalutamide [
         <a href="#rid2">
          2,3
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/16351.html" rel="external">
          "Castration-resistant prostate cancer: Treatments targeting the androgen pathway", section on 'Chemotherapy-naïve'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5705454">
         <span class="h3">
          Nilutamide
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9701" href="/z/d/drug information/9701.html" rel="external">
          Nilutamide
         </a>
         has a half-life of approximately two days. In addition to the side effects due to its antiandrogenic properties, specific side effects include delayed adaptation to darkness in 25 percent of patients, nausea in 10 percent, reversible increases in hepatic transaminases in up to 8 percent, and alcohol intolerance in 5 percent [
         <a href="#rid8">
          8
         </a>
         ]. There are also rare reports of interstitial lung disease caused by nilutamide [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
         Biochemical responses to
         <a class="drug drug_general" data-topicid="9701" href="/z/d/drug information/9701.html" rel="external">
          nilutamide
         </a>
         have been observed after progression on other antiandrogens [
         <a href="#rid10">
          10,11
         </a>
         ]. Males with a prior antiandrogen withdrawal response may be significantly more likely to have a response to nilutamide than those without such a response [
         <a href="#rid11">
          11
         </a>
         ]. (See
         <a class="local">
          'Antiandrogen withdrawal'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h3">
          Flutamide
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8471" href="/z/d/drug information/8471.html" rel="external">
          Flutamide
         </a>
         has a low priority in sequential hormonal therapies because of its toxicity profile and limited activity. Flutamide has a half-life of approximately five hours and is almost completely excreted in the urine. In addition to its antiandrogenic side effects, diarrhea, nausea, and vomiting are relatively frequent side effects. Although hepatotoxicity is uncommon, it can be fatal; serum aminotransferases should be closely monitored during therapy [
         <a href="#rid12">
          12,13
         </a>
         ].
        </p>
        <p>
         The limited efficacy of
         <a class="drug drug_general" data-topicid="8471" href="/z/d/drug information/8471.html" rel="external">
          flutamide
         </a>
         is illustrated by a trial conducted by the European Organisation for Research and Treatment of Cancer (EORTC) in which 201 males were randomly assigned to either flutamide (250 mg three times daily) or
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         (5 mg four times daily) [
         <a href="#rid14">
          14
         </a>
         ]. There were no significant differences between the groups in the time to progression, overall survival, subjective response rate, biochemical response rate, or duration of response. However, patients receiving prednisone had less pain, fatigue, anorexia, and gastrointestinal distress, and had better quality of life.
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h3">
          Cyproterone acetate
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9295" href="/z/d/drug information/9295.html" rel="external">
          Cyproterone acetate
         </a>
         (CPA), a steroidal antiandrogen, can act both by blocking the androgen receptor and by inhibiting androgen synthesis. CPA at doses of 100 to 300 mg per day is considered to be as effective as estrogens or
         <a class="drug drug_general" data-topicid="8471" href="/z/d/drug information/8471.html" rel="external">
          flutamide
         </a>
         , with better tolerability [
         <a href="#rid15">
          15
         </a>
         ]. However, CPA has some estrogenic activity, and its use has been associated with a risk of deep venous and arterial thromboses. In addition, liver toxicity can complicate long-term use. Patients with existing or previously treated meningiomas should not be prescribed CPA at doses of 25 mg per day or higher because of a reported association between long-term CPA use and multiple meningiomas [
         <a href="#rid16">
          16,17
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5220.html" rel="external">
          "Epidemiology, pathology, clinical features, and diagnosis of meningioma", section on 'High-dose cyproterone'
         </a>
         .)
        </p>
        <p>
         CPA is not approved in the United States for the treatment of males with advanced prostate cancer.
        </p>
        <p class="headingAnchor" id="H442096182">
         <span class="h2">
          Antiandrogen withdrawal
         </span>
         <span class="headingEndMark">
          —
         </span>
         Discontinuation of treatment with an antiandrogen may result in a clinical or biochemical (PSA) response; antiandrogen withdrawal responses have been observed following discontinuation of the antiandrogens [
         <a href="#rid4">
          4,18-20
         </a>
         ]. The mechanism of the antiandrogen withdrawal response is not known.
        </p>
        <p>
         Alternative therapy should not be initiated until adequate time has elapsed to rule out a withdrawal response. This waiting period is based on the half-life of the drug administered. Response or a decline in serum PSA may not occur for three to six weeks after treatment with
         <a class="drug drug_general" data-topicid="9154" href="/z/d/drug information/9154.html" rel="external">
          bicalutamide
         </a>
         and
         <a class="drug drug_general" data-topicid="9701" href="/z/d/drug information/9701.html" rel="external">
          nilutamide
         </a>
         , which have half-lives of approximately one week and two days, respectively. With
         <a class="drug drug_general" data-topicid="8471" href="/z/d/drug information/8471.html" rel="external">
          flutamide
         </a>
         , which has a half-life of five hours, one to two weeks is adequate to observe for a possible withdrawal response. Antiandrogen withdrawal responses also have been reported following discontinuation of
         <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">
          abiraterone
         </a>
         [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
         The role of antiandrogen withdrawal was studied in males with CRPC in a multicenter phase III trial [
         <a href="#rid18">
          18
         </a>
         ]. In this trial, 260 patients who had progressed on androgen deprivation therapy were randomly assigned to antiandrogen withdrawal plus simultaneous
         <a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">
          ketoconazole
         </a>
         , or antiandrogen withdrawal alone with ketoconazole reserved for subsequent use upon progression. More patients had a PSA response or an objective tumor response when ketoconazole was initiated immediately rather than waiting to see if an antiandrogen withdrawal response occurred (27 versus 11 and 20 versus 2 percent, respectively). However, there was no statistically significant difference in overall survival with the two treatment strategies (15.3 versus 16.7 months, p = 0.94).
        </p>
        <p>
         Two other observational series that each included over 200 patients observed antiandrogen withdrawal PSA response rates of 15 and 21 percent of cases, respectively [
         <a href="#rid4">
          4,22
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H5705704">
         <span class="h1">
          OTHER AGENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         A number of other hormonal therapies have at least some activity in males with CRPC. There are no comparator trials, and the choice of approach is empiric.
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h2">
          Ketoconazole
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">
          Ketoconazole
         </a>
         is an imidazole antifungal agent that inhibits steroid hormone synthesis, and it also has a direct cytotoxic effect on prostatic cancer cells in vitro [
         <a href="#rid23">
          23
         </a>
         ]. Ketoconazole is less specific than
         <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">
          abiraterone
         </a>
         , which is also an inhibitor of steroid hormone synthesis. However, it may retain a role in some patients given its much lower cost. Treatment with ketoconazole is generally initiated after allowing for a potential response from the withdrawal of an antiandrogen. (See
         <a class="local">
          'Antiandrogen withdrawal'
         </a>
         above.)
        </p>
        <p>
         The usual dose of
         <a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">
          ketoconazole
         </a>
         is 200 to 400 mg three times per day. Ketoconazole requires a low gastric pH for maximum absorption and thus should be taken on an empty stomach [
         <a href="#rid24">
          24
         </a>
         ]. In addition, antacids, proton pump inhibitors, and histamine H2-receptor antagonists should be avoided, if possible. The use of ketoconazole is also complicated by multiple complex drug interactions. (For specific interactions, use the
         <a class="external" href="/drug-interactions">
          drug interactions program
         </a>
         included with UpToDate.)
        </p>
        <p>
         Adverse effects include nausea and vomiting in up to one-half of patients, skin rash in 10 percent, fatigue, nail dystrophy, asthenia, and gynecomastia.
         <a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">
          Ketoconazole
         </a>
         can cause hepatotoxicity; liver function should be monitored at two weeks after initiating therapy and monthly thereafter. High doses of ketoconazole can cause adrenal insufficiency. Thus, ketoconazole is usually administered with concurrent
         <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">
          hydrocortisone
         </a>
         , which also has an antitumor effect and can complicate the interpretation of the results with ketoconazole.
        </p>
        <p>
         The benefit of
         <a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">
          ketoconazole
         </a>
         was addressed in a phase III trial conducted by the Cancer and Leukemia Group B (CALGB 9583), in which 260 patients with CRPC who had progressed on androgen deprivation therapy (ADT) were randomly assigned to antiandrogen withdrawal plus simultaneous ketoconazole or to antiandrogen withdrawal alone with ketoconazole reserved for subsequent use upon progression [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Among 128 patients assigned to antiandrogen withdrawal plus immediate
         <a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">
          ketoconazole
         </a>
         , a prostate-specific antigen (PSA) decline ≥50 percent was observed in 27 percent, and an objective tumor response was observed in 10 of 50 patients (20 percent) with measurable disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the group of 132 patients assigned to antiandrogen withdrawal alone, 108 were treated with
         <a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">
          ketoconazole
         </a>
         plus
         <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">
          hydrocortisone
         </a>
         when PSA progression was documented. In these males, 35 of 108 (32 percent) had a PSA response, and 3 of 41 (7 percent) with measurable disease had an objective response.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H919059981">
         <span class="h2">
          Glucocorticoids
         </span>
         <span class="headingEndMark">
          —
         </span>
         Glucocorticoids,
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         in particular, are an integral component of many treatment regimens for metastatic CRPC, but for different reasons:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Several studies have shown significant subjective and objective improvement in males with CRPC who receive glucocorticoids as monotherapy [
         <a href="#rid14">
          14,25-28
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A survival benefit has been shown from the addition of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         to both
         <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">
          docetaxel
         </a>
         and
         <a class="drug drug_general" data-topicid="15577" href="/z/d/drug information/15577.html" rel="external">
          cabazitaxel
         </a>
         [
         <a href="#rid29">
          29,30
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6945.html" rel="external">
          "Chemotherapy in advanced castration-resistant prostate cancer", section on 'Docetaxel versus mitoxantrone'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6945.html" rel="external">
          "Chemotherapy in advanced castration-resistant prostate cancer", section on 'Cabazitaxel'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          Prednisone
         </a>
         is also used to reduce side effects related to mineralocorticoid excess resulting from inhibition of 17-alpha-hydroxylase (CYP17), a key enzyme in androgen synthesis, from agents such as
         <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">
          abiraterone
         </a>
         [
         <a href="#rid31">
          31
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/16351.html" rel="external">
          "Castration-resistant prostate cancer: Treatments targeting the androgen pathway", section on 'Abiraterone'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Several mechanisms might underlie the antitumor effect of glucocorticoids in advanced prostate cancer. Glucocorticoids (eg,
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         ,
         <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">
          hydrocortisone
         </a>
         ) reduce the pituitary production of adrenocorticotropic hormone (ACTH), resulting in suppression of adrenal steroidogenesis including adrenal androgens. Other possible mechanisms include direct inhibition of tumor growth by disruption of intracellular signaling pathways [
         <a href="#rid32">
          32,33
         </a>
         ] and/or suppression of tumor lymphangiogenesis [
         <a href="#rid34">
          34,35
         </a>
         ].
        </p>
        <p>
         Some data on the activity of glucocorticoids come from trials in which steroids served as a control group [
         <a href="#rid14">
          14,26,27,36-38
         </a>
         ]. As an example, in one trial,
         <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">
          hydrocortisone
         </a>
         (40 mg/day) was compared with hydrocortisone plus
         <a class="drug drug_general" data-topicid="10291" href="/z/d/drug information/10291.html" rel="external">
          suramin
         </a>
         in males with CRPC; 16 percent of those given cortisone alone had a decline in serum PSA &gt;50 percent, while 28 percent had improved bone pain [
         <a href="#rid26">
          26
         </a>
         ]. Similarly, in another trial comparing
         <a class="drug drug_general" data-topicid="9660" href="/z/d/drug information/9660.html" rel="external">
          mitoxantrone
         </a>
         plus hydrocortisone with hydrocortisone alone, 22 percent of males receiving hydrocortisone alone had &gt;50 percent decline in serum PSA [
         <a href="#rid27">
          27
         </a>
         ]. In a third trial of males previously treated with
         <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">
          docetaxel
         </a>
         who were assigned to
         <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">
          abiraterone
         </a>
         plus
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         versus placebo plus prednisone, prednisone alone was associated with pain palliation in 29 percent but a &gt;50 percent decline in PSA in only 6 percent [
         <a href="#rid36">
          36,38
         </a>
         ].
        </p>
        <p>
         There are only limited data addressing the optimal glucocorticoid regimen when used as monotherapy. In one single-center trial, 75 males were randomly assigned to either
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         (0.5 mg/day) or
         <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">
          prednisolone
         </a>
         (5 mg twice daily) [
         <a href="#rid25">
          25
         </a>
         ]. The PSA response rate was higher with dexamethasone (41 versus 22 percent), as was the median time to disease progression (10 versus 5 months), compared with prednisolone. In the absence of more robust data, dexamethasone may be the preferred glucocorticoid.
        </p>
        <p>
         Whether there is benefit to switching to a different glucocorticoid in patients who progress while receiving a glucocorticoid for advanced disease (eg,
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         in conjunction with
         <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">
          docetaxel
         </a>
         or
         <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">
          abiraterone
         </a>
         ) is unclear. At least some data support the view that switching from prednisone to
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         benefits some males who have limited progression while receiving abiraterone (ie, a rise in PSA and/or limited radiographic progression) for metastatic CRPC [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H442097127">
         <span class="h2">
          Megestrol acetate
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9603" href="/z/d/drug information/9603.html" rel="external">
          Megestrol acetate
         </a>
         is a synthetic progestin that may act through several mechanisms [
         <a href="#rid40">
          40,41
         </a>
         ]. Megestrol acetate is rarely used since it has only limited activity and has been associated with tumor flare and risk of deep venous thrombosis.
        </p>
        <p>
         The most extensive data using
         <a class="drug drug_general" data-topicid="9603" href="/z/d/drug information/9603.html" rel="external">
          megestrol acetate
         </a>
         come from a multicenter trial in which 149 males with advanced prostate cancer were randomly assigned to either low-dose (160 mg/day) or high-dose (640 mg/day) megestrol acetate. A &gt;50 percent decrease in serum PSA was observed in 14 and 9 percent of low-dose and high-dose treatment groups. Median survival was the same in both groups (11 and 12 months, respectively).
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h2">
          Estrogens
         </span>
         <span class="headingEndMark">
          —
         </span>
         Diethylstilbestrol (DES) at a dose of 1 mg/day and other estrogen preparations, such as transdermal
         <a class="drug drug_general" data-topicid="9422" href="/z/d/drug information/9422.html" rel="external">
          estradiol
         </a>
         , may have a role in some patients, where they are available.
        </p>
        <p>
         High doses of estrogens compete with androgens for the androgen receptor and have a cytotoxic effect on human androgen-sensitive and androgen-insensitive prostate cancer cells in vitro [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          DES
         </strong>
         – DES formerly was widely used in the treatment of metastatic CRPC, but data supporting its use come primarily in the setting of initial hormone therapy for castration-sensitive advanced disease. The potential role of DES (1 mg daily) as a second-line agent was evaluated in a trial in which 58 males who had progressed on gonadotropin-releasing hormone (GnRH) agonist therapy were randomly assigned to either DES or
         <a class="drug drug_general" data-topicid="9154" href="/z/d/drug information/9154.html" rel="external">
          bicalutamide
         </a>
         [
         <a href="#rid43">
          43
         </a>
         ]. Both the PSA response rate and median response durations were similar in the two groups (23 versus 31 percent and 9 versus 12 months, respectively). However, bicalutamide was better tolerated. Despite the prophylactic use of 75 mg of
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         daily in the DES group, three of seven patients with adverse effects had cardiovascular toxicity (congestive heart failure, pulmonary embolism, stroke).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         DES is inexpensive, but it is limited in availability worldwide; it is not commercially available in tablet or capsule form in the United States or Canada. However, at least in the United States, DES can be obtained from compounding pharmacies.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Transdermal estrogen
         </strong>
         – Transdermal estrogen may be an option for males with CRPC, especially those with hot flashes, but the optimal dose is not established.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The transdermal route of estrogen administration avoids first pass through the liver, and the consequent hepatic overexpression of proteins, including those affecting coagulation, thereby diminishing cardiovascular toxicity associated with oral estrogens [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The best data on efficacy and toxicity come from the Prostate Adenocarcinoma TransCutaneous Hormones (PATCH) study that randomly assigned males with locally advanced or metastatic prostate cancer scheduled to initiate indefinite hormone therapy to transdermal
         <a class="drug drug_general" data-topicid="9422" href="/z/d/drug information/9422.html" rel="external">
          estradiol
         </a>
         ([E2], 4 x 100 microg per 24 hours, changed twice weekly, reduced to three patches twice weekly if castrate at four weeks) or a luteinizing hormone releasing hormone agonist (LHRHa), and specifically addressed cardiovascular toxicity as a primary outcome [
         <a href="#rid45">
          45-47
         </a>
         ]. Notably, the males included in this trial had castration sensitive, and not CRPC.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The initial pilot phase in 254 males showed transdermal E2 achieved equivalent castration rates to LHRHa without the early excess cardiovascular morbidity or mortality previously seen with oral estrogen [
         <a href="#rid45">
          45
         </a>
         ]. Subsequent analyses of this dataset showed a number of other potential benefits of transdermal E2 compared with LHRHa, including improved bone mineral density [
         <a href="#rid48">
          48
         </a>
         ], more favorable metabolic profiles, better quality of life over six months of ADT, although with increased likelihood of gynecomastia [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In the latest expanded analysis of 1694 males randomly assigned to transdermal E2 or LHRHa, at a median follow-up of 3.9 years, castration rates at one and three months were 65 and 93 percent for the LHRH agonist, and 83 and 93 percent for transdermal E2 [
         <a href="#rid47">
          47
         </a>
         ]. Fatal cardiovascular events developed in 26 (2 percent), 15 in the LHRHa group and 11 treated with transdermal E2. The total number of cardiovascular events was not significantly higher with transdermal E2 (by 36 months, 8 versus 7.2 percent), nor was the time to first cardiovascular event significantly earlier (HR 1.11, 95% CI 0.80-1.53). Notably, however, 30 of the 89 cardiovascular events occurring in the transdermal E2 group (34 percent) occurred more than three months after transdermal E2 was stopped or changed to LHRHa.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Accrual to this trial (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT00303784%3Fterm%3DNCT00303784%26draw%3D2%26rank%3D1&amp;token=nbsXe3i4qfUea5RCPRHtOS7yhoEzH%2BMCpwZ1%2F1ekxPMEvlsQTgIMtOc9UZ12aLyc%2F4AKmxlbzeHTM6nF9feQBGtARm6Y1F9l8VtQHJFPgqI%3D&amp;TOPIC_ID=6942" target="_blank">
          NCT00303784
         </a>
         ) continues, with progression-free and overall survival as endpoints.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Additional information on the efficacy of transdermal estrogen in males with castration-resistant disease was provided in a phase II trial of 24 males with prostate cancer progressing after primary ADT [
         <a href="#rid49">
          49
         </a>
         ]. The dose of transdermal estrogen was 0.6 mg per 24 hours, administered as six 0.1 mg per 24-hour patches, replaced every seven days. Three of the 24 males (12.5 percent) had a confirmed PSA reduction &gt;50 percent, and estimated median time to disease progression was 12 weeks (95% CI 4.6 to 19.4 weeks). Toxicity was modest and there were no thromboembolic complications.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1481804560">
         <span class="h1">
          ASSESSMENT DURING TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         For males with CRPC who are undergoing chemotherapy, periodic assessment should be geared toward identifying signs and symptoms of disease progression, as well as the side effects of treatment. Serial evaluation of serum prostate-specific antigen (PSA) is the mainstay of testing. Consensus-based guidelines from the National Comprehensive Cancer Network (NCCN) recommend testing PSA every three to six months during treatment for advanced prostate cancer [
         <a href="#rid50">
          50
         </a>
         ]. Most clinicians make decisions about the need for radiographic evaluation based on changes in PSA values and/or the development of new symptoms. Therapeutic changes are usually not made based on a rising PSA alone.
        </p>
        <p>
         Assessment strategies during treatment for CRPC are discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/112896.html" rel="external">
          "Overview of the treatment of castration-resistant prostate cancer (CRPC)", section on 'Assessment during treatment'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H630126737">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/117831.html" rel="external">
          "Society guideline links: Diagnosis and management of prostate cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/880.html" rel="external">
          "Patient education: Treatment for advanced prostate cancer (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Continuation of ADT
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Androgen deprivation therapy (ADT) is generally the initial treatment for males with advanced prostate cancer in combination with chemotherapy or combined with a second-generation androgen-targeted therapy or both. Despite high response rates to the initial hormone therapy, nearly all males eventually develop progressive castration-resistant disease. Subsequent management utilizes sequential application of various treatments. (See
         <a class="medical medical_review" href="/z/d/html/16351.html" rel="external">
          "Castration-resistant prostate cancer: Treatments targeting the androgen pathway"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with castration-resistant prostate cancer (CRPC) whose initial hormonal therapy included medical orchiectomy, we suggest that the gonadotropin-releasing hormone (GnRH) agonist or antagonist be continued throughout subsequent therapies so as to maintain suppression of testicular androgen production (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Continuation of androgen deprivation therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antiandrogen withdrawal
         </strong>
         – If a first generation antiandrogen was a component of initial ADT, discontinuation of treatment with the antiandrogen may result in a clinical or biochemical (prostate-specific antigen [PSA]) response. (See
         <a class="local">
          'Antiandrogen withdrawal'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other approaches
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A number of newer approaches have demonstrated improved overall survival in males with CRPC, but these have not been compared with each other in randomized clinical trials  (
         <a class="graphic graphic_table graphicRef127197" href="/z/d/graphic/127197.html" rel="external">
          table 1
         </a>
         ). The optimal sequencing of these therapies and their timing relative to older alternative endocrine approaches remain uncertain. (See
         <a class="medical medical_review" href="/z/d/html/16351.html" rel="external">
          "Castration-resistant prostate cancer: Treatments targeting the androgen pathway"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6945.html" rel="external">
          "Chemotherapy in advanced castration-resistant prostate cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/17128.html" rel="external">
          "Bone metastases in advanced prostate cancer: Management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">
          Abiraterone
         </a>
         and
         <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">
          enzalutamide
         </a>
         generally are the initial choice for second-line endocrine therapy in males with CRPC after failure of ADT if the patient has not already received a second generation androgen-targeted therapy for castration-sensitive disease. (See
         <a class="local">
          'Abiraterone and enzalutamide'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The most common and least controversial use of alternative androgen-receptor-directed therapies is in patients with biochemical progression following first-line ADT in whom standard imaging shows minimal or no disease. While active surveillance is appropriate in such patients, many have biochemical responses to less potent androgen-receptor-directed agents (eg,
         <a class="drug drug_general" data-topicid="9154" href="/z/d/drug information/9154.html" rel="external">
          bicalutamide
         </a>
         ), with unknown long-term clinical benefit. (See
         <a class="local">
          'Older antiandrogens'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A number of other hormonal therapies have at least some activity in males with CRPC. There are no comparator trials, and the choice of approach is empiric. (See
         <a class="local">
          'Other agents'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1970170012">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         We are saddened by the death of Nicholas Vogelzang, MD, who passed away in September 2022. UpToDate gratefully acknowledges Dr. Vogelzang's role as Section Editor on this topic, and his dedicated and longstanding involvement with the UpToDate program.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Virgo KS, Basch E, Loblaw DA, et al. Second-Line Hormonal Therapy for Men With Chemotherapy-Naïve, Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical Opinion. J Clin Oncol 2017; :JCO2017728030.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Penson DF, Armstrong AJ, Concepcion R, et al. Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial. J Clin Oncol 2016; 34:2098.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shore ND, Chowdhury S, Villers A, et al. Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. Lancet Oncol 2016; 17:153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suzuki H, Okihara K, Miyake H, et al. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. J Urol 2008; 180:921.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scher HI, Liebertz C, Kelly WK, et al. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. J Clin Oncol 1997; 15:2928.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joyce R, Fenton MA, Rode P, et al. High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. J Urol 1998; 159:149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kucuk O, Fisher E, Moinpour CM, et al. Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study (SWOG 9235). Urology 2001; 58:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Decensi AU, Boccardo F, Guarneri D, et al. Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. The Italian Prostatic Cancer Project. J Urol 1991; 146:377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfitzenmeyer P, Foucher P, Piard F, et al. Nilutamide pneumonitis: a report on eight patients. Thorax 1992; 47:622.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davis NB, Ryan CW, Stadler WM, Vogelzang NJ. A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy. BJU Int 2005; 96:787.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kassouf W, Tanguay S, Aprikian AG. Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails. J Urol 2003; 169:1742.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wysowski DK, Fourcroy JL. Flutamide hepatotoxicity. J Urol 1996; 155:209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wysowski DK, Freiman JP, Tourtelot JB, Horton ML 3rd. Fatal and nonfatal hepatotoxicity associated with flutamide. Ann Intern Med 1993; 118:860.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fosså SD, Slee PH, Brausi M, et al. Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group. J Clin Oncol 2001; 19:62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schröder FH, Collette L, de Reijke TM, Whelan P. Prostate cancer treated by anti-androgens: is sexual function preserved? EORTC Genitourinary Group. European Organization for Research and Treatment of Cancer. Br J Cancer 2000; 82:283.
          </a>
         </li>
         <li class="breakAll">
          Drug safety update, Medicines and Healthcare products Regulatory Agency (MHRA) volume 3, issue 3, October 2009. www.mhra.gov.uk.
         </li>
         <li class="breakAll">
          Restrictions in use of cyproterone due to meningioma risk. European Medicines Agency. Available at: https://www.ema.europa.eu/en/news/restrictions-use-cyproterone-due-meningioma-risk (Accessed on December 21, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Small EJ, Halabi S, Dawson NA, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 2004; 22:1025.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sartor AO, Tangen CM, Hussain MH, et al. Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426). Cancer 2008; 112:2393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodriguez-Vida A, Bianchini D, Van Hemelrijck M, et al. Is there an antiandrogen withdrawal syndrome with enzalutamide? BJU Int 2015; 115:373.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caffo O, Palermo A, Veccia A, et al. Biochemical and objective response to abiraterone acetate withdrawal: incidence and clinical relevance of a new scenario for castration-resistant prostate cancer. Urology 2013; 82:1090.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998; 339:1036.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eichenberger T, Trachtenberg J, Toor P, Keating A. Ketoconazole: a possible direct cytotoxic effect on prostate carcinoma cells. J Urol 1989; 141:190.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blum RA, D'Andrea DT, Florentino BM, et al. Increased gastric pH and the bioavailability of fluconazole and ketoconazole. Ann Intern Med 1991; 114:755.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Venkitaraman R, Lorente D, Murthy V, et al. A randomised phase 2 trial of dexamethasone versus prednisolone in castration-resistant prostate cancer. Eur Urol 2015; 67:673.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Small EJ, Meyer M, Marshall ME, et al. Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. J Clin Oncol 2000; 18:1440.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999; 17:2506.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tannock I, Gospodarowicz M, Meakin W, et al. Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 1989; 7:590.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376:1147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351:1502.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Attard G, Reid AH, A'Hern R, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009; 27:3742.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nishimura K, Nonomura N, Satoh E, et al. Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer. J Natl Cancer Inst 2001; 93:1739.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fakih M, Johnson CS, Trump DL. Glucocorticoids and treatment of prostate cancer: a preclinical and clinical review. Urology 2002; 60:553.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yano A, Fujii Y, Iwai A, et al. Glucocorticoids suppress tumor angiogenesis and in vivo growth of prostate cancer cells. Clin Cancer Res 2006; 12:3003.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yano A, Fujii Y, Iwai A, et al. Glucocorticoids suppress tumor lymphangiogenesis of prostate cancer cells. Clin Cancer Res 2006; 12:6012.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Logothetis CJ, Basch E, Molina A, et al. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol 2012; 13:1210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2015; 16:152.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012; 13:983.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xiong X, Qiu S, Yi X, et al. Steroid switch after progression on abiraterone plus prednisone in patients with metastatic castration-resistant prostate cancer: A systematic review. Urol Oncol 2021; 39:754.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Geller J, Albert J, Geller S, et al. Effect of megestrol acetate (Megace) on steroid metabolism and steroid-protein binding in the human prostate. J Clin Endocrinol Metab 1976; 43:1000.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leinung MC, Liporace R, Miller CH. Induction of adrenal suppression by megestrol acetate in patients with AIDS. Ann Intern Med 1995; 122:843.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Landström M, Damber JE, Bergh A. Estrogen treatment postpones the castration-induced dedifferentiation of Dunning R3327-PAP prostatic adenocarcinoma. Prostate 1994; 25:10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manikandan R, Srirangam SJ, Pearson E, et al. Diethylstilboestrol versus bicalutamide in hormone refractory prostate carcinoma: a prospective randomized trial. Urol Int 2005; 75:217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ockrim JL, Lalani el-N, Kakkar AK, Abel PD. Transdermal estradiol therapy for prostate cancer reduces thrombophilic activation and protects against thromboembolism. J Urol 2005; 174:527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Langley RE, Cafferty FH, Alhasso AA, et al. Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09). Lancet Oncol 2013; 14:306.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gilbert DC, Duong T, Kynaston HG, et al. Quality-of-life outcomes from the Prostate Adenocarcinoma: TransCutaneous Hormones (PATCH) trial evaluating luteinising hormone-releasing hormone agonists versus transdermal oestradiol for androgen suppression in advanced prostate cancer. BJU Int 2017; 119:667.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Langley RE, Gilbert DC, Duong T, et al. Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme. Lancet 2021; 397:581.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Langley RE, Kynaston HG, Alhasso AA, et al. A Randomised Comparison Evaluating Changes in Bone Mineral Density in Advanced Prostate Cancer: Luteinising Hormone-releasing Hormone Agonists Versus Transdermal Oestradiol. Eur Urol 2016; 69:1016.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bland LB, Garzotto M, DeLoughery TG, et al. Phase II study of transdermal estradiol in androgen-independent prostate carcinoma. Cancer 2005; 103:717.
          </a>
         </li>
         <li class="breakAll">
          NCCN Clinical Practice Guidelines in Oncology. Available at: https://www.nccn.org/professionals/physician_gls/default.aspx (Accessed on August 15, 2019).
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 6942 Version 41.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28441112" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Second-Line Hormonal Therapy for Men With Chemotherapy-Naïve, Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical Opinion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26811535" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26774508" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18635218" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9256137" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Bicalutamide for advanced prostate cancer: the natural versus treated history of disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9400459" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11445479" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study (SWOG 9235).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1856935" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. The Italian Prostatic Cancer Project.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1412120" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Nilutamide pneumonitis: a report on eight patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16153201" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12686822" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7490837" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Flutamide hepatotoxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7683180" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Fatal and nonfatal hepatotoxicity associated with flutamide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11134196" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10646878" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Prostate cancer treated by anti-androgens: is sexual function preserved? EORTC Genitourinary Group. European Organization for Research and Treatment of Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10646878" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Prostate cancer treated by anti-androgens: is sexual function preserved? EORTC Genitourinary Group. European Organization for Research and Treatment of Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10646878" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Prostate cancer treated by anti-androgens: is sexual function preserved? EORTC Genitourinary Group. European Organization for Research and Treatment of Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15020604" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18383517" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24906049" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Is there an antiandrogen withdrawal syndrome with enzalutamide?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24001702" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Biochemical and objective response to abiraterone acetate withdrawal: incidence and clinical relevance of a new scenario for castration-resistant prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9761805" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2908948" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Ketoconazole: a possible direct cytotoxic effect on prostate carcinoma cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2012358" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Increased gastric pH and the bioavailability of fluconazole and ketoconazole.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25457497" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : A randomised phase 2 trial of dexamethasone versus prednisolone in castration-resistant prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10735891" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10561316" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2709088" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20888992" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15470213" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19470933" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11717335" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12385906" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Glucocorticoids and treatment of prostate cancer: a preclinical and clinical review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16707595" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Glucocorticoids suppress tumor angiogenesis and in vivo growth of prostate cancer cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17062674" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Glucocorticoids suppress tumor lymphangiogenesis of prostate cancer cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23142059" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25601341" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22995653" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34330654" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Steroid switch after progression on abiraterone plus prednisone in patients with metastatic castration-resistant prostate cancer: A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/62759" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Effect of megestrol acetate (Megace) on steroid metabolism and steroid-protein binding in the human prostate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7741369" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Induction of adrenal suppression by megestrol acetate in patients with AIDS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8022707" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Estrogen treatment postpones the castration-induced dedifferentiation of Dunning R3327-PAP prostatic adenocarcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16215308" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Diethylstilboestrol versus bicalutamide in hormone refractory prostate carcinoma: a prospective randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16006886" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Transdermal estradiol therapy for prostate cancer reduces thrombophilic activation and protects against thromboembolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23465742" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27753182" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Quality-of-life outcomes from the Prostate Adenocarcinoma: TransCutaneous Hormones (PATCH) trial evaluating luteinising hormone-releasing hormone agonists versus transdermal oestradiol for androgen suppression in advanced prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33581820" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26707868" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : A Randomised Comparison Evaluating Changes in Bone Mineral Density in Advanced Prostate Cancer: Luteinising Hormone-releasing Hormone Agonists Versus Transdermal Oestradiol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15641029" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Phase II study of transdermal estradiol in androgen-independent prostate carcinoma.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
